Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.20 +0.00 (+0.00%)
As of: Oct 1, 2026 · 9:31 AM EDT

Telomir Pharmaceuticals (TELO) Non Operating Income (2023 - 2024)

Updated

Telomir Pharmaceuticals (TELO) reported Non Operating Income of $15,445 for Q3 2024, compared with -$757,173 a year earlier.

Analysis

Telomir Pharmaceuticals (TELO) Non Operating Income (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -73.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 387.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Telomir Pharmaceuticals 82.53 Mn 82.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 15,445.00
Sep 30, 2023 -757,173.00
API Access

Telomir Pharmaceuticals Non Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-income&ticker=TELO&period=max&api_key=YOUR_API_KEY